[Experimental expansion and antitumor effects of LAK cells from cancer patient's peripheral blood].
To augment the in vitro expansion of LAK cells, we added highly purified human recombinant interleukin-2, phytohemagglutinin and accessory cells (Uc cells) to the LAK culture system, with which huge number of LAK cells (LAK-L) were generated from originally small number of peripheral blood lymphocytes of cancer patients. These LAK-L cells exhibited similar antitumor activities in vitro and in vivo, as compared with LAK-S cells (LAK cells activated in short term culture). The phenotyping results suggested that there was more expression of IL-2 receptors in the LAK-L group than in the LAK-S group. The rapid proliferation of LAK-L cells was characterized by the expansion of OKT8 positive cells in the LAK-L populations.
Zhang
B X
BX
Beijing Medical University.
D000818:Animals; D016516:CD4-CD8 Ratio; D002277:Carcinoma / Q000276:immunology / Q000628:therapy*; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010835:Phytohemagglutinins; D015375:Receptors, Interleukin-2 / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D007376:Interleukin-2; D010835:Phytohemagglutinins; D015375:Receptors, Interleukin-2